The promiscuity of ARF interactions with the proteasome

The tumor suppressor ARF is one of the most important oncogenic stress sensors in mammalian cells. Its effect is exerted through the interaction with different cellular partners, often resulting in their functional inactivation. This review focuses on the role played by the proteasome in ARF regulation of protein turnover and the function of most of its interacting partners. Specific proteasome components appear to be involved in the regulation of ARF turnover, bringing to light a complex network of interactions between ARF and the proteasome.

[1]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[2]  E. Brambilla,et al.  Human ARF binds E2F1 and inhibits its transcriptional activity , 2001, Oncogene.

[3]  Jun Qin,et al.  ARF-BP1/Mule Is a Critical Mediator of the ARF Tumor Suppressor , 2005, Cell.

[4]  T. Shenk,et al.  Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Kefford,et al.  p14ARF Interacts with the SUMO-Conjugating Enzyme Ubc9 and Promotes the Sumoylation of Its Binding Partners , 2005, Cell cycle.

[6]  A. Ciechanover,et al.  The Tumor Suppressor Protein p16INK4a and the Human Papillomavirus Oncoprotein-58 E7 Are Naturally Occurring Lysine-less Proteins That Are Degraded by the Ubiquitin System , 2004, Journal of Biological Chemistry.

[7]  L. Linares,et al.  The proteasome regulates HIV-1 transcription by both proteolytic and nonproteolytic mechanisms. , 2007, Molecular cell.

[8]  J. Chen,et al.  Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survival , 2007, Proceedings of the National Academy of Sciences.

[9]  P. Carmeliet,et al.  Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. , 2003, The Journal of clinical investigation.

[10]  S. Lowe,et al.  Tumor suppression by Ink4a-Arf: progress and puzzles. , 2003, Current opinion in genetics & development.

[11]  A. Rivett,et al.  Regulation of proteasome complexes by γ-interferon and phosphorylation , 2001 .

[12]  Y. Shaul,et al.  A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. , 2005, Genes & development.

[13]  Mei-Ling Kuo,et al.  N-terminal polyubiquitination and degradation of the Arf tumor suppressor. , 2004, Genes & development.

[14]  C. Sherr.  Divorcing ARF and p53: an unsettled case , 2006, Nature Reviews Cancer.

[15]  C. Hill,et al.  Characterization of Recombinant REGα, REGβ, and REGγ Proteasome Activators* , 1997, The Journal of Biological Chemistry.

[16]  M. Serrano,et al.  Antiviral action of the tumor suppressor ARF , 2006, The EMBO journal.

[17]  E. Friedberg,et al.  The 19S regulatory complex of the proteasome functions independently of proteolysis in nucleotide excision repair. , 1999, Molecular cell.

[18]  C. Slaughter,et al.  Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain). , 1992, The Journal of biological chemistry.

[19]  J. Adams.  The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.

[20]  K. Tanaka,et al.  Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. , 2000, The Biochemical journal.

[21]  N. Sharpless,et al.  Targeting of C-Terminal Binding Protein (CtBP) by ARF Results in p53-Independent Apoptosis , 2006, Molecular and Cellular Biology.

[22]  B. O’Malley,et al.  Specific Amino Acid Residues in the Basic Helix-Loop-Helix Domain of SRC-3 Are Essential for Its Nuclear Localization and Proteasome-Dependent Turnover , 2006, Molecular and Cellular Biology.

[23]  Y. Shaul,et al.  HBV X protein targets HIV Tat-binding protein 1. , 2001, Virology.

[24]  S. Amente,et al.  p14ARF is capable of promoting HIV-1 Tat degradation , 2008, Cell cycle.

[25]  A. Szalay,et al.  The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1alpha (HIF-1alpha ) and inhibits HIF-1-mediated transcription. , 2001, The Journal of biological chemistry.

[26]  F. Zindy,et al.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Lance F. Barton,et al.  Immune Defects in 28-kDa Proteasome Activator γ-Deficient Mice1 , 2004, The Journal of Immunology.

[28]  E. Brambilla,et al.  p14ARF Activates a Tip60-Dependent and p53-Independent ATM/ATR/CHK Pathway in Response to Genotoxic Stress , 2006, Molecular and Cellular Biology.

[29]  A. Prescott,et al.  p14 Arf Promotes Small Ubiquitin-like Modifier Conjugation of Werners Helicase* , 2004, Journal of Biological Chemistry.

[30]  James M. Roberts,et al.  Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. , 2007, Molecular cell.

[31]  Charles J. Sherr,et al.  Physical and Functional Interactions of the Arf Tumor Suppressor Protein with Nucleophosmin/B23 , 2004, Molecular and Cellular Biology.

[32]  A. Rivett,et al.  Regulation of proteasome complexes by gamma-interferon and phosphorylation. , 2001, Biochimie.

[33]  David Hawke,et al.  Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. , 2003, Molecular cell.

[34]  C. Ross,et al.  Parkin Mediates Nonclassical, Proteasomal-Independent Ubiquitination of Synphilin-1: Implications for Lewy Body Formation , 2005, The Journal of Neuroscience.

[35]  J. Herman,et al.  Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel–Lindau protein , 2003, Nature Genetics.

[36]  K. Honda,et al.  Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. , 2003, Nature.

[37]  D. Delia,et al.  REGγ proteasome activator is involved in the maintenance of chromosomal stability , 2008, Cell Cycle.

[38]  D. Lane,et al.  P14ARF promotes accumulation of SUMO‐1 conjugated (H)Mdm2 , 2002, FEBS letters.

[39]  R. Kefford,et al.  p14ARF Regulates E2F-1 Ubiquitination and Degradation via a p53-Dependent Mechanism , 2007, Cell cycle.

[40]  P. Pelicci,et al.  Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. , 2006, Cancer research.

[41]  Raffaele Calogero,et al.  Functional and Physical Interaction of the Human ARF Tumor Suppressor with Tat-binding Protein-1* , 2004, Journal of Biological Chemistry.

[42]  A. Datta,et al.  ARF Directly Binds DP1: Interaction with DP1 Coincides with the G1 Arrest Function of ARF , 2005, Molecular and Cellular Biology.

[43]  K. Jeang,et al.  A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter , 2003, Nature Cell Biology.

[44]  A. Gartel,et al.  Myc-ARF (Alternate Reading Frame) Interaction Inhibits the Functions of Myc* , 2004, Journal of Biological Chemistry.

[45]  Yafen Huang,et al.  Tumor Suppressor ARF Promotes Non-classic Proteasome-independent Polyubiquitination of COMMD1* , 2008, Journal of Biological Chemistry.

[46]  A. Datta,et al.  Differential Regulation of E2F1, DP1, and the E2F1/DP1 Complex by ARF , 2002, Molecular and Cellular Biology.

[47]  A. Szalay,et al.  The p14ARF Tumor Suppressor Protein Facilitates Nucleolar Sequestration of Hypoxia-inducible Factor-1α (HIF-1α) and Inhibits HIF-1-mediated Transcription* , 2001, The Journal of Biological Chemistry.

[48]  C. Larsen,et al.  Human ARF protein interacts with Topoisomerase I and stimulates its activity , 2001, Oncogene.

[49]  Pengbo Zhou.  REGgamma: a shortcut to destruction. , 2006, Cell.

[50]  G. Peters,et al.  Stability of nucleolar versus non-nucleolar forms of human p14ARF , 2004, Oncogene.

[51]  D. Lane,et al.  Oligomerization of the Human ARF Tumor Suppressor and Its Response to Oxidative Stress* , 2003, Journal of Biological Chemistry.

[52]  F. J. Herrera,et al.  Proteasome Parts at Gene Promoters , 2002, Science.

[53]  A. McCormack,et al.  Global organization and function of mammalian cytosolic proteasome pools: Implications for PA28 and 19S regulatory complexes. , 2006, Molecular biology of the cell.

[54]  Thomas Kodadek,et al.  Recruitment of a 19S Proteasome Subcomplex to an Activated Promoter , 2002, Science.

[55]  H. Ke,et al.  Essential Role of the B23/NPM Core Domain in Regulating ARF Binding and B23 Stability* , 2006, Journal of Biological Chemistry.

[56]  L. Guerrini,et al.  Inhibition of p63 Transcriptional Activity by p14ARF: Functional and Physical Link between Human ARF Tumor Suppressor and a Member of the p53 Family , 2004, Molecular and Cellular Biology.

[57]  C. J. Barnes,et al.  Growth Factor Regulation of a 26S Proteasomal Subunit in Breast Cancer , 2005, Clinical Cancer Research.

[58]  Qinghong Zhang,et al.  Homeodomain Interacting Protein Kinase 2 Promotes Apoptosis by Downregulating the Transcriptional Corepressor CtBP , 2003, Cell.

[59]  C. Hill,et al.  Characterization of recombinant REGalpha, REGbeta, and REGgamma proteasome activators. , 1997, The Journal of biological chemistry.

[60]  C. Korgaonkar,et al.  Nucleophosmin (B23) Targets ARF to Nucleoli and Inhibits Its Function , 2005, Molecular and Cellular Biology.

[61]  A. Datta,et al.  Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. , 2004, Genes & development.

[62]  David M. Livingston,et al.  p19ARF targets certain E2F species for degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[63]  C. Sherr,et al.  N-Terminal Polyubiquitination of the ARF Tumor Suppressor, A Natural Lysine-Less Protein , 2004, Cell cycle.

[64]  F. J. Herrera,et al.  Transcription. Proteasome parts at gene promoters. , 2002, Science.

[65]  Lance F. Barton,et al.  Immune defects in 28-kDa proteasome activator gamma-deficient mice. , 2004, Journal of immunology.

[66]  C. Sherr,et al.  Sumoylation induced by the Arf tumor suppressor: a p53-independent function. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[67]  Pengbo Zhou.  REGγ: A Shortcut to Destruction , 2006, Cell.

[68]  A. Malovannaya,et al.  The SRC-3/AIB1 Coactivator Is Degraded in a Ubiquitin- and ATP-Independent Manner by the REGγ Proteasome , 2006, Cell.

[69]  V. Villella,et al.  TBP-1 protects the human oncosuppressor p14ARF from proteasomal degradation , 2007, Oncogene.

[70]  Kevin Ryan,et al.  The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.

[71]  D. O’Rourke,et al.  Induction of the Tat-binding protein 1 gene accompanies the disabling of oncogenic erbB receptor tyrosine kinases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[72]  M. Kasahara,et al.  Growth Retardation in Mice Lacking the Proteasome Activator PA28γ* , 1999, The Journal of Biological Chemistry.

[73]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[74]  M. Pariat,et al.  Ubiquitinylation is not an absolute requirement for degradation of c- Jun protein by the 26 S proteasome , 1995, The Journal of Biological Chemistry.